奥氮平与氯氮平治疗精神分裂症对照研究

A controlled study on olanzapine vs. clozapine in the treatment of schizophrenics

目的评价奥氮平与氯氮平治疗精神分裂症的临床疗效及安全性。方法将69例首次住院的精神分裂症患者随机分为两组,分别给予奥氮平和氯氮平治疗,疗程8w。于治疗前及治疗2w、4w、8w末采用简明精神病量表评定疗效,副反应量表评定不良反应。结果治疗8w末,奥氮平组显效率75.76%,有效率90.91%;氯氮平组分别为72.22%、88.89%;两组疗效相当(χ2=0.939,P>0.81)。简明精神病量表评分,两组治疗2w末起均较治疗前有极显著性下降(P<0.01),并随治疗时间的延续呈持续性下降;同期两组间比较无显著性差异(P>0.05)。两组不良反应均为轻至中度,对症处理后均缓解或消失;奥氮平组不良反应严重程度及发生率均小于氯氮平组,但两组间差异均无显著性(P均>0.05)。结论奥氮平治疗精神分裂症疗效显著,与氯氮平相当,且安全性高,依从性好。

Objective To evaluate the clinical efficacies and safety of olanzapine vs. clozapine in the treatment of schizophrenia. Methods 69 first-hospitalized schizophrenis were randomly divided into olanzapine and clozapine groups for 8 weeks. The clinical efficacies were assessed with the Brief Psychiatric Rating Scale（BPRS） and adverse effects with the Treatment Emergent Symptom Scale （TESS） before treatment and at the ends of 2nd,4th and 8th week treatment. Results At the end of the 8th week,excellence and effective rates were 75.76% and 90.91% in olanzapine group and 72.22% and 88.89% in clozapine group respectively,efficacies of both the 2 groups were equivalent（P〈0.81）. Since the end of the 2nd week,the BPRS scores of the 2 groups lowered very more significantly compared with pretreatment（P〈0.01） ,and did continously along with treatment lasting; there was no significant differ- ence in synchronization group comparison（P〈0.05）. Adverse effects of both groups were mild to moderate and relieved or disappeared after symptomatic treatment;there were no significant differnces in severiry and incidence of adverse effects between the 2 groups（P〈0.05）. Conclusion Olanzapine has significant fiicacy,higher safety and better compliance in the schizophenia.